US Bancorp
RAPP icon

US Bancorp’s Rapport Therapeutics RAPP Stock Holding History

US Bancorp’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$583 Buy
14
+9
+180% +$331 ﹤0.01% 4037
2026
Q1 		$156 Buy
+5
New +$141 ﹤0.01% 4115
2025
Q2 		– Sell
-144
Closed -$1.44K – 4352
2025
Q1 		$1.44K Buy
+144
New +$1.87K ﹤0.01% 3932

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Arch Venture Management
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Sofinnova Investments
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Polar Capital Holdings
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

US Bancorp's RAPP Position: Q2 2026 in Review

US Bancorp increased its Rapport Therapeutics (RAPP) stake by 180% in Q2 2026, buying an estimated $331 and bringing the position to 14 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

US Bancorp first reported a position in RAPP in Q1 2025 and has held it in 3 quarters since. The position peaked at $1.44K in Q1 2025. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • US Bancorp held 14 shares of Rapport Therapeutics worth $583 as of Q2 2026.
  • US Bancorp bought 9 Rapport Therapeutics shares in Q2 2026, an estimated $331.
  • Rapport Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #4037 holding.
  • US Bancorp first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • US Bancorp's Rapport Therapeutics position peaked at $1.44K in Q1 2025.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.